Posted by Michael Wonder on 01 Jun 2021
Paratek Pharmaceuticals announces FDA approval of Nuzyra (omadacycline) oral only dosing regimen for the treatment of community-acquired bacterial pneumonia
1 June 2021 - Oral only dosing for the treatment of CABP expands the commercial opportunity for primary care promotion.
Paratek Pharmaceuticals today announced that the U.S. FDA has approved the Company’s supplemental new drug application for the oral only dosing regimen of Nuzyra for the treatment of adults with CABP.
